Renal related adverse events (Figure 10)
The following outcomes were studied for renal-related adverse events:
acute kidney injury, hospitalization due to acute kidney injury,
discontinuation of trial regimen due to acute kidney injury and
hospitalization due to acute renal failure. Four out of seven studies[5,10,14,15] reported acute kidney injury, and the
pooled analysis revealed that treatment with Finerenone was associated
with a slightly lower risk of acute kidney injury (RR = 0.94 [0.84,
1.05] p= 0.30, I2= 0%) whereas hospitalization due to acute kidney
injury, discontinuation of treatment regimen due to acute kidney injury
and hospitalization due to acute renal failure was reported by three out
of seven studies [5,10,14] and the pooled analysis
revealed that the risk of hospitalization due to acute kidney injury and
risk of hospitalization due to acute renal failure was similar in both
treatment groups, (RR = 0.99 [0.80, 1.22] p=0.91; I2= 0%) and (RR =
0.97 [0.80, 1,18] p= 0.76; I2= 0%) respectively, whereas the risk
of discontinuation of treatment regimen due to acute kidney injury was
higher in Finerenone group (RR = 1.38 [0.69, 2.75] p = 0. 37; I2=
0%)